Extending Therapy Options in Treating Lipid DisordersA Clinical Review of Cerivastatin, a Novel HMG-CoA Reductase Inhibitor

被引：0
|
作者：
Evan A. Stein
机构：
[1] Medical Research Laboratories,
来源：
Drugs | 1998年 / 56卷
关键词：
Adis International Limited; Pravastatin; Lovastatin; Fluvastatin; Cerivastatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Cerivastatin is a third generation pure enantiomeric HMG-CoA reductase inhibitor. It reduces low density lipoprotein (LDL)-cholesterol by 22 to 44% at doses of 0.1 to 0.8 mg/day The drug has been extensively evaluated for more than 5 years in clinical trials and is currently marketed in a number of countries at doses of 0.1 to 0.3 mg/day.
引用
收藏
页码：25 / 31
页数：6
相关论文
共 50 条
  • [1] Extending therapy options in treating lipid disorders - A clinical review of cerivastatin, a novel HMG-CoA reductase inhibitor
    Stein, EA
    DRUGS, 1998, 56 (Suppl 1) : 25 - 31
  • [2] Biopharmaceutical profile of cerivastatin, a novel HMG-CoA reductase inhibitor
    Muck, W
    Ochmann, K
    Mazzu, A
    Lettieri, J
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 130 - 130
  • [3] Biopharmaceutical profile of cerivastatin:: a novel HMG-CoA reductase inhibitor
    Mück, W
    Ochmann, K
    Mazzu, A
    Lettieri, J
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1999, 27 (03) : 107 - 114
  • [4] Cerivastatin, a novel HMG-CoA reductase inhibitor: Efficacy and tolerability
    Schmage, N
    Cagatay, M
    Park, SM
    Lommerzheim, A
    Schopen, U
    HERZ KREISLAUF, 2000, 32 (7-8): : 242 - 252
  • [5] Preclinical safety evaluation of cerivastatin, a novel HMG-CoA reductase inhibitor
    von Keutz, E
    Schlüter, G
    AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (4B): : 11J - 17J
  • [6] Cerivastatin (BAY w 6228):: A novel HMG-CoA reductase inhibitor
    Kuhlmann, J
    Mück, W
    Bischoff, H
    von Keutz, E
    Llewellyn, M
    CARDIOVASCULAR DRUG REVIEWS, 1998, 16 (03): : 236 - 263
  • [7] In vitro antitumor activity of cerivastatin, a novel and potent HMG-CoA reductase inhibitor
    Feleszko, W
    Mlynarczuk, I
    Nowis, D
    FEBS LETTERS, 2001, 503 (2-3) : 219 - 220
  • [8] Cerivastatin: pharmacology of a novel synthetic and highly active HMG-CoA reductase inhibitor
    Bischoff, H
    Angerbauer, R
    Bender, J
    Bischoff, E
    Faggiotto, A
    Petzinna, D
    Pfitzner, J
    Porter, MC
    Schmidt, D
    Thomas, G
    ATHEROSCLEROSIS, 1997, 135 (01) : 119 - 130
  • [9] Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin
    Ritter, W
    Ochmann, K
    Muck, W
    Kuhlmann, J
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1997, 355 (04) : 477 - 477
  • [10] Cerivastatin: the low-dose HMG-COA reductase inhibitor
    Tikkanen, MJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (01) : 161 - 166
12345